Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 22:9:768.
doi: 10.3389/fendo.2018.00768. eCollection 2018.

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas

Xiaoshuang Liu  1 , Chao Tang  2 , Guodao Wen  3 , Chunyu Zhong  4 , Jin Yang  4 , Junhao Zhu  4 , Chiyuan Ma  2
Affiliations
Review

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas

Xiaoshuang Liu et al. Front Endocrinol (Lausanne). .

Abstract

Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions. The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms.

Keywords: bromocriptine; cabergoline; dopamine agonists; programmed cell death; prolactinomas.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The pathways of dopamine and dopamine agonists in prolactinomas.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. (2009) 23:543–54. 10.1016/j.beem.2009.05.008 - DOI - PubMed
    1. Lleva RR, Inzucchi SE. Diagnosis and management of pituitary adenomas. Curr Opin Oncol. (2011) 23:53–60. 10.1097/CCO.0b013e328341000f - DOI - PubMed
    1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. . Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol. (2006) 65:265–73. 10.1111/j.1365-2265.2006.02562.x - DOI - PubMed
    1. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. (2006) 27:485–534. 10.1210/er.2005-9998 - DOI - PubMed
    1. Melmed S. Pathogenesis of pituitary tumors. Endocrinol Metab Clin North Am. (1999) 28:1–12. 10.1016/S0889-8529(05)70055-4 - DOI - PubMed

LinkOut - more resources